Measurement of WT1-mRNA in Acute Myeloid Leukemia Patients

Measurement of WT1-mRNA as a Prognostic Factor in Acute Myeloid Leukemia - Measurement of WT1-mRNA in Acute Myeloid Leukemia Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1090220061

Enrollment

100

Registered

2011-06-02

Start date

2011-06-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Interventions

Intervention type: Name of intervention: Dose form / Japanese Medical Device Nomenclature: Route of administration / Site of application: Dose per administration: Dosing frequency / Frequency of use:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Untreated, de novo AML patients, who are positi ve for WT1-mRNA at diagnosis and without previous history of myelodysplastic syndrome.

Exclusion criteria

Exclusion criteria: AML cases who did not achieve complete remission after one-/two- course of remission-induction therapy.

Design outcomes

Primary

Measure	Time frame
Correlation between the comparison of WT1-mRNA of pre- with post-chemotherapy and 2-year relapse-free survival.	—

Secondary

Measure	Time frame
Correlation between characteristics of the patients and the change of WT1-mRNA level and survival.	—

Countries

Japan

Contacts

Public ContactISHIYAMA, Ken

Tokyo Metropolitan Ohtsuka Hospital

ishiyama-knz@umin.ac.jp+81-3-3941-3211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026